Cellaïon is a Belgian biotechnology company focused on developing advanced therapies aimed at liver repair and organ regeneration. Their primary technology, HepaStem®, utilizes cell signaling mechanisms to restore the body's natural regenerative processes, particularly in the liver, which is essential for numerous bodily functions. By targeting chronic liver diseases, Cellaïon aims to halt disease progression, manage inflammation, and prevent the accumulation of fibrous tissue, ultimately facilitating liver recovery and regeneration.

The company is engaged in clinical research, including a Phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure. Their research highlights the potential of human allogeneic liver-derived progenitor cells (HALPCs) in improving liver health, as evidenced by recent publications that demonstrate their efficacy in both in vitro and in vivo models. Cellaïon's commitment to innovation in liver therapies positions them at the forefront of biotechnology aimed at addressing life-threatening liver conditions.

Belgium

Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem

Cellaïon

Company Details